Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. Laura Lin is an Executive Director in the BioMedicine Design Unit, Pfizer’s Biotherapeutic Discovery organization. She leads the Molecular Design, Profiling, and Production group responsible for biotherapeutic discovery and optimization using structure and computational-based design approach, early stage developability assessment, bioinformatics, and non-GMP biotherapeutic production. Laura is a member of the BioMedicine Design Leadership Team, providing strategic input and directions on antibody discovery and optimization across Pfizer’s large molecule portfolio.
Laura brings with her 20 years’ experience in the pharma industry. She came to Pfizer in 2009 via the Wyeth acquisition. Laura held a PhD in Biophysics from New York University. She is a co-author of over 35 peer-reviewed publications and co-inventor of 10 issued patents and patent applications.